Holen Sie sich die Stockscreener-App
90.73
1.10%
0.99
Schlusskurs vom Vortag:
$89.74
Offen:
$88.82
24-Stunden-Volumen:
832.74K
Relative Volume:
1.76
Marktkapitalisierung:
$4.40B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-20.03
EPS:
-4.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+0.70%
1M Leistung:
-4.09%
6M Leistung:
+20.68%
1J Leistung:
+28.60%
1-Tages-Spanne:
$87.69
$93.12
1-Wochen-Bereich:
$87.69
$94.64
52-Wochen-Spanne:
$64.11
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
90.73 | 4.40B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Franklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Barclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Sleep Apnea Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma - Barchart
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 4%Here's What Happened - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lowered by State Street Corp - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 7.9% in November - MarketBeat
Axsome Therapeutics' SWOT analysis: strong growth, pipeline potential lift stock - Investing.com
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? - MSN
Captrust Financial Advisors Acquires Shares of 5,722 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wellington Management Group LLP Acquires 8,125 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Fmr LLC Has $97.79 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Charles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is RTW Investments LP's 2nd Largest Position - MarketBeat
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HighVista Strategies LLC Sells 20,650 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market - The Globe and Mail
Smoking Cessation and Nicotine Addiction Market Growth - openPR
PDT Partners LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
9,466 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fred Alger Management LLC - MarketBeat
Trend Tracker for (AXSM) - Stock Traders Daily
Bellevue Group AG Decreases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Eventide Asset Management LLC Has $74.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: Focus On AXS-12 Targeting Narcolepsy, Just Released Positive Data (NASDAQ:AXSM) - Seeking Alpha
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Cynosure Group LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - AOL
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
HC Wainwright Has Bullish Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome's AXS-12 shows efficacy in narcolepsy trial By Investing.com - Investing.com Canada
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy - MSN
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Positive Phase III data in narcolepsy from Axsome - The Pharma Letter
Axsome Therapeutics Announces AXS-12 Achieves Primary - GlobeNewswire
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week - Yahoo Finance
Axsome's AXS-12 shows efficacy in narcolepsy trial - Investing.com India
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy - The Manila Times
Loomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome's AXS-12 Shows 77% Reduction in Narcolepsy Attacks in Phase 3 Trial Success | AXSM Stock News - StockTitan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome shares reiterate Buy rating on strong Q3 results By Investing.com - Investing.com UK
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet? - Simply Wall St
Eagle Asset Management Inc. Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Option Exercise |
3.67 |
11,016 |
40,429 |
21,018 |
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):